newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Trial's Safety Monitoring Committee Recommends Maintaining Initial Cell Dose Level for Next Cohort of Patients Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports early efficacy results showing